Clinical trials: Pulmonary Artery Hypertension
Systemic Sclerosis-Associated PAH
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious, life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the connective tissue characterized by scarring (fibrosis)…
- Trial name
- NCT01086540
- Testing
- Rituximab, CMRI, prednisone
- Where
- 17 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Arterial Hypertension
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
AMB-320/321-E was designed to provide long-term, controlled monitoring of pulmonary arterial hypertension (PAH) patients treated with ambrisentan (AMB) in order to properly define the adverse event profile associated with this…
- Trial name
- NCT00578786
- Testing
- ambrisentan
- Where
- 22 sites in Argentina, Brazil and 2 more
- Volunteers
- 383 people
- Sponsor
- Gilead Sciences
High Altitude Pulmonary Hypertension
Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live >2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.
- Trial name
- NCT06489756
- Testing
- Echocardiography
- Where
- Kyrgyzstan
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Attention Deficit Disorder With Hyperactivity, Asthma
Study of an Intervention to Improve Problem List Accuracy and Use
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer
- Trial name
- MAPLE (NCT01105923)
- Testing
- MAPLE
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure, Pulmonary Arterial Hypertension
Non-invasive Pulmonary Artery Prediction
Cardiac remote monitoring devices have expanded our ability to track physiological changes used in the diagnosis and management of patients with cardiac disease.
- Trial name
- ADOPTS (NCT05622695)
- Testing
- catheterization
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Silverleaf Medical Sciences INC
Pulmonary Arterial Hypertension, Insulin Resistance
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity.
- Trial name
- NCT03288025
- Testing
- Nutrition and Exercise
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The Cleveland Clinic
Pulmonary Hypertension
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension.
- Trial name
- NCT00125918
- Testing
- tadalafil
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 406 people
- Sponsor
- Eli Lilly and Company
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
The purpose of this study is to evaluate the effect of esomeprazole, a proton pump inhibitor, on treprostinil pharmacokinetics.
- Trial name
- NCT00963027
- Testing
- Treprostinil diethanolamine, Esomeprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Goal Oriented Strategy to Preserve Ejection Fraction Trial
In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in patients with pulmonary…
- Trial name
- GOSPEL (NCT03236818)
- Testing
- ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Arterial Hypertension, Healthy
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand [11C]PBR28) in the lungs of patients living with PAH relative to age matched controls.
- Trial name
- NCT05745961
- Testing
- TSPO PET scan (11C-PBR28)
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called I-Neb. In these patients, the non compliance of the treatment becomes its ineffective and increases the complications and mortality of the…
- Trial name
- Inventa (NCT01468545)
- Testing
- Iloprost (Ventavis inhaled, BAYQ6256)
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Dapagliflozin in Pulmonary Arterial Hypertension
The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension
- Trial name
- DAPAH (NCT05179356)
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Mads Ersbøll
Hypertension, Pulmonary
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
Researchers are looking for ways to treat people with a type of high blood pressure in the lungs called pulmonary arterial hypertension (PAH).
- Trial name
- NCT07899905
- Testing
- Sotatercept
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Pulmonary, Altitude Sickness
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
During ascent to high altitude there is a physiologic response to hypoxia that results in an elevated pulmonary arterial pressure associated with decreased exercise performance, altitude-induced pulmonary hypertension, and high…
- Trial name
- NCT02024386
- Testing
- Riociguat
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Richard Moon
Pulmonary Arterial Hypertension
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year.
- Trial name
- REPAIR (NCT02310672)
- Testing
- Macitentan
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 89 people
- Sponsor
- Actelion
Healthy, Healthy Adult
Sleep-Assessment in Patients Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on sleeping parameters by polygraphy in healthy individuals, who live permanently >2600m.
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07801950
- Testing
- Descent from 2850m to sea level and re-ascent back to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06072417
- Testing
- Assessment without intervention at High altitude, Relocation to sea level for 2 days
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Methamphetamine-Associated Heart Failure, Methamphetamine-Associated Pulmonary Arterial Hypertension
Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions
The purpose of this study is to evaluate the feasibility and preliminary effectiveness of increasing control over stimulant use and physical health through incentivized rehabilitation (INSPIRE).
- Trial name
- INSPIRE (NCT07915882)
- Testing
- Increasing control over stimulant use and physical health through incentivized rehabilitation, Usual Care
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Michael Incze